Scientists discover anti-HIV-1 antibody treatment suppresses viral infection

HIV-1 infection remains an incurable public health problem

In the present study, researchers conducted a clinical study in which HIV-infected individuals received seven doses of a combination of two broadly neutralizing antibodies, 3BNC117 and 10-1074, over 20 weeks in the presence or absence of ART, Its safety, tolerability and antiviral activity were studied

The study found that the pharmacokinetic profiles of 3BNC117 and 10-1074 were independent of concomitant antiretroviral drugs during viral suppression and did not change after multiple dosing over 20 weeks

Figure virological and pharmacokinetic follow-up of individual participants

These data suggest that antibody administration affects the HIV-1 reservoir, but more studies, larger and longer, are needed to determine the exact effect of antibody immunotherapy on the reservoir

Note: The original text has been deleted

Reference: Gaebler, C.